Predictive Biomarkers Analysis Service for ICI-based Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs) have emerged as a promising approach to treat various types of cancers. However, the response to ICI-based cancer immunotherapy can vary significantly among patients, highlighting the need for predictive biomarkers that can help identify individuals who are likely to benefit from these treatments.

Creative Biolabs provides the analysis service of predictive biomarkers for ICI-based cancer immunotherapy, focusing on four key aspects: tumor cells-related biomarkers analysis, tumor microenvironment (TME) phenotype biomarkers analysis, liquid biopsy biomarkers analysis, and host-related markers analysis.

Fig.1 Overview of predictive biomarkers for ICI efficacy. (Bai, et al., 2020)

Tumor Cells-Related Biomarkers Analysis

Understanding the characteristics of tumor cells is crucial for predicting the response to ICI-based cancer immunotherapy. We provide several tumor cells-related biomarkers analysis for their predictive potential, including:

• Tumor mutational burden (TMB) analysis
• PD-L1 expression analysis
• Neoantigen load analysis
• DDR pathway analysis
• Specific mutated gene pathways analysis
• DNA damage response pathways analysis

TME Phenotype Biomarkers Analysis

One of the key TME phenotype biomarkers is the presence of tumor-infiltrating lymphocytes (TILs). TILs, particularly CD8+ T cells, have been associated with improved response to ICIs in various cancer types.

Additionally, the immunosuppressive TME, characterized by the presence of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), has been associated with resistance to ICIs. Therefore, analyzing the composition and functional status of TILs, Tregs, and MDSCs can help predict the response to ICI-based cancer immunotherapy.

Liquid Biopsy Biomarkers Analysis

Liquid biopsy has emerged as a non-invasive and convenient method for biomarker analysis in cancer patients. By analyzing various components, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, liquid biopsy can provide valuable information about tumor dynamics and treatment response. Typically, we provide the following biomarkers analysis:

• Peripheral blood cell biomarkers analysis
• Circulating tumor DNA (ctDNA) biomarkers analysis

Host-Related Markers Analysis

Apart from tumor-specific biomarkers, host-related markers play a crucial role in predicting the response to ICI-based cancer immunotherapy. The genetic makeup and immune profile of patients can influence their ability to mount an effective anti-tumor immune response. We provide biomarkers analysis for the following host-related markers:

• Intestinal commensal microbiota
• Host germline genetics
• Gut microbiome Analysis
• Microsatellite instability (MSI) Analysis

Additionally, considering that the type of ICIs is more correlated with treatment, Creative Biolabs also provides predictive markers analysis for different ICI types, including but not limited to:

• Predictive markers analysis of PD-1 Blockade
• Predictive markers analysis of CTLA-4 Blockade
• Predictive markers analysis of PD-L1 Blockade

By analyzing these biomarkers, researchers can make informed decisions and personalize treatment strategies, ultimately improving patient outcomes.

Creative Biolabs is committed to advancing the field of predictive biomarker analysis and providing innovative solutions to enhance the efficacy of ICI-based cancer immunotherapy. Please feel free to contact us for more about our Treg related services.

Reference

1. Bai, R.; et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker research. 2020, 8: 1-17.

For Research Use Only | Not For Clinical Use

Resources

Download our brochure